Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
This week, we will discuss why a large registry cohort was needed to move past decades of scattered case reports and clarify the true risk of hydralazine‑associated vasculitis. When rare events hide in noise, only scale can reveal the signal. Can population‑level data finally bring this paradox into focus?
Summary of the STEPS trial which will be a twitter spaces discussion
This week, we will discuss the HIT trial- a large randomized study challenging one of the most reflexive responses in hospital medicine: see hyponatremia, fix the sodium. But what if correcting the number doesn’t change what actually matters?
Read the #TenTweetNephJC summary of the ADMIRAL study, examining how dd-cfDNA monitoring may help us manage our patients with renal transplants.
1. Does transplant medicine have a new blood test that is better than creatinine?
— Nephrology Jrnl Club (@NephJC) July 1, 2022
Aye aye ADMIRAL 🫡
Join us as we recap last week's #NephJC chat on this edition of #TenTweetNephJC brought to you by @jamiekwillows and @michaelturk6 pic.twitter.com/gAS70VKG8i